This discrepancy might stem from the Revised Criteria, which allow AD to be defined with at least one positive Core1 biomarker, even if the assays themselves specifically measure Aβ (A) or tau (T1) pathophysiology, thus being less restrictive [8]. The gene discussed is MAPT; the disease is Alzheimer disease.